# OnCo record mds (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mds/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mds" ;
  schema:name "Myelodysplastic syndromes / neoplasms (MDS)"@en ;
  schema:description "Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."@en ;
  schema:url <https://onco.cc/cancers/mds/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Myelodysplastic_syndrome> ;
  owl:sameAs <http://www.wikidata.org/entity/Q954625> ;
  schema:citation <https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008>, <https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/systemic-mastocytosis/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/transfusion-support/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/tim3/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/magrolimab/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/drugs/dorocubicel/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/taiho/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/differentiation-syndrome/> ;
  onco:trials <https://onco.cc/trials/nct05883956/>, <https://onco.cc/trials/nct04256317/>, <https://onco.cc/trials/nct04064060/> ;
  onco:people <https://onco.cc/people/uwe-platzbecker/>, <https://onco.cc/people/pierre-fenaux/> ;
  onco:journals <https://onco.cc/journals/leukemia-research/> ;
  onco:pipeline <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/tuspetinib/>, <https://onco.cc/drugs/bexmarilimab/>, <https://onco.cc/drugs/spartalizumab/>, <https://onco.cc/drugs/sabatolimab/>, <https://onco.cc/drugs/ard103/> ;
  onco:standardOfCare <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/trials/bmt-ctn-1102/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/trials/telesto/> .